Balyasny Asset Management
OSIR

Balyasny Asset Management’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Balyasny Asset Management’s Portfolio OSIR Stock Details OSIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-15,050
Closed -$156K – 1743
2015
Q4 		$156K Buy
+15,050
New +$204K ﹤0.01% 1127

Other funds holding OSIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $337M AUM 22.95% 1-Year Est. Return

Balyasny Asset Management's OSIR Position: Q1 2016 in Review

Balyasny Asset Management sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2016, closing a stake of 15,050 shares — an estimated $156K sold.

Balyasny Asset Management first reported a position in OSIR in Q4 2015 and held it in 1 quarter. The position peaked at $156K in Q4 2015. 80 funds tracked by Wall St. Rank hold OSIR as of Q1 2016.

  • Balyasny Asset Management reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 15,050 Osiris Therapeutics, Inc. Common Stock shares in Q1 2016, an estimated $156K.
  • Balyasny Asset Management first reported a position in Osiris Therapeutics, Inc. Common Stock in Q4 2015 and held it in 1 quarter.
  • Balyasny Asset Management's Osiris Therapeutics, Inc. Common Stock position peaked at $156K in Q4 2015.
  • 80 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2016.

Based on Balyasny Asset Management's 13F filing for Q1 2016, filed 16 May 2016.